SRR17866819
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 44.2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.720
- ANGIOGENESIS+0.610
- TNFA_SIGNALING_VIA_NFKB+0.610
- INFLAMMATORY_RESPONSE+0.530
- IL6_JAK_STAT3_SIGNALING+0.450
- HYPOXIA+0.420
- COMPLEMENT+0.410
- ALLOGRAFT_REJECTION+0.390
- COAGULATION+0.380
- MYOGENESIS+0.380
Top 10 suppressed
- E2F_TARGETS-0.650
- MYC_TARGETS_V1-0.600
- MYC_TARGETS_V2-0.600
- G2M_CHECKPOINT-0.590
- OXIDATIVE_PHOSPHORYLATION-0.510
- DNA_REPAIR-0.320
- PANCREAS_BETA_CELLS-0.300
- CHOLESTEROL_HOMEOSTASIS-0.270
- FATTY_ACID_METABOLISM-0.260
- PEROXISOME-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c6396737-3587-46a7-808d-963eebe41224 | — | — | 0.930 |
| 2 | ERR2208937 | — | — | 0.925 |
| 3 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.924 |
| 4 | 4925248f-21e2-476e-937c-02e0a748c77b | — | — | 0.920 |
| 5 | C3N-02923 | — | cohortMD2 | 0.913 |
| 6 | C3L-02164 | — | cohortMD2 | 0.911 |
| 7 | SRR26320074 | — | — | 0.911 |
| 8 | C3N-02144 | — | cohortA1 | 0.911 |
| 9 | C3L-02170 | — | cohortMD2 | 0.908 |
| 10 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.720 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.610 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.610 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |